Apolipoprotein A-I [ApoA1] (human):Fc (human) (rec.)

CHF 585.00
In stock
CHI-HF-210ApoA1-C100100 µgCHF 585.00
More Information
Product Details
Synonyms Apolipoprotein A1; ApoA-I; Apo-AI
Product Type Protein
Properties
Source/Host HEK 293 cells
Sequence The extracellular domain of human ApoA1 (aa 25-267) is fused to the N-terminus of the Fc region of human IgG1.
Crossreactivity Human
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.06EU/μg protein (LAL test; Lonza).
Reconstitution Reconstitute with sterile water to a concentration of 100μg/ml.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data NCBI reference AAH05380.1: ApoA1 (human)
Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Apolipoprotein A-I [Apolipoprotein A1; ApoA1] is a 28kDa glycoprotein that is the major protein component of high density lipoprotein (HDL) particles. ApoA1is involved in the esterification of cholesterol as a cofactor of lecithin-cholesterol acyltransferase (LCAT), which is responsible for the formation of most plasma cholesteryl esters, and thus plays a major role in cholesterol efflux from peripheral cells. Therefore, as a major component of the HDL complex, ApoA1 plays a central role in the reverse transport of cholesterol from peripheral tissues to the liver. Upon HDL particles return to the liver, ApoA1 binds to the scavenger receptor SR-B1 and the &beta-;chain of ATP synthase on hepatocytes. Hepatocytes internalize the particles and pass the cholesterol into bile for excretion. Polymorphisms of ApoA1 are associated with dysregulation of HDL levels and cholesterol homeostasis. Genetic defects of ApoA1 have been associated with HDL deficiencies, including Tangier disease and with systemic non-neuropathic amyloidosis. ApoA1, either as a free molecule or in lipidated particulate form, induces the release of insulin from pancreatic islets in a process that is dependent on ABCA1 and SR-B1. ApoA1 has also been characterized as a prostacyclin stabilizing factor and thus may have an anticlotting effect.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.